Acumen Pharmaceuticals, Inc. 8-K

What Happened
Acumen Pharmaceuticals, Inc. (ABOS) filed a Form 8‑K on May 12, 2026 reporting financial results and business highlights for the quarter ended March 31, 2026. The company furnished an earnings press release (Exhibit 99.1) and posted an updated corporate presentation (Exhibit 99.2) to its investor website reflecting its cash, cash equivalents and marketable securities balance as of March 31, 2026. The report was signed by Matthew Zuga, Chief Financial Officer and Chief Business Officer.

Key Details

• Filing date: May 12, 2026; reporting period: quarter ended March 31, 2026.
• Earnings press release furnished as Exhibit 99.1 (dated May 12, 2026).
• Corporate presentation posted/updated on the investor site (Exhibit 99.2) to reflect cash, cash equivalents and marketable securities as of March 31, 2026.
• 8‑K executed by Matthew Zuga, CFO & Chief Business Officer.

Why It Matters
This filing gives investors the company’s most recent quarterly results and an updated snapshot of liquidity. The earnings press release and updated presentation are primary sources for revenue, expense, cash‑balance and business‑progress details; investors should review those exhibits and the investor presentation on Acumen’s website for specifics on performance and cash runway. The 8‑K does not report any management changes, mergers, or other material corporate actions beyond the results and presentation update.